公开(公告)号：US4652518A

公开(公告)日：1987-03-24

申请号：US507788

申请日：1983-06-24

Applicant: Pirjo H. Makela ,  Maija K. Leinonen ,  Marjatta H. Nurminen-Kalliokoski ,  Pekka A. I. Saikku

Inventor： Pirjo H. Makela ,  Maija K. Leinonen ,  Marjatta H. Nurminen-Kalliokoski ,  Pekka A. I. Saikku

IPC: A61K35/74 ,  A61K39/00 ,  A61K39/118 ,  C12Q1/04 ,  G01N33/569 ,  G01N33/53 ,  G01N33/546 ,  G01N33/561 ,  G01N33/571

CPC classification number: G01N33/56927 ,  G01N2333/295 ,  G01N2400/50 ,  Y10S435/879 ,  Y10S436/811 ,  Y10S436/823

Abstract: A preparation for the detection of chlamydial infections using lipopolysaccharide of Re-lipopolysaccharide mutants of gram-negative bacteria. The lipopolysaccharide preparation is used in the production of group-specific antibodies to chlamydiae for diagnostic purposes or for the demonstration of antibodies to chlamydial group antigen in specimens.

Abstract translation: 使用革兰氏阴性菌的再脂多糖突变体的脂多糖检测衣原体感染的制剂。 脂多糖制剂用于生产针对衣原体的组特异性抗体用于诊断目的或用于证明样品中衣原体组抗原的抗体。

公开(公告)号：US2415234A

公开(公告)日：1947-02-04

申请号：US57274045

申请日：1945-01-13

Applicant: SQUIBB & SONS INC

Inventor： EDWARD BUNNEY WILLIAM ,  CLARA NIGG

IPC: A61K39/118

CPC classification number: A61K39/118

公开(公告)号：US2324646A

公开(公告)日：1943-07-20

申请号：US38233441

申请日：1941-03-08

Applicant: SQUIBB & SONS INC

Inventor： RAKE GEOFFREY W ,  SHAFFER MORRIS F ,  MCKEE CLIRA M

IPC: A61K39/118

CPC classification number: A61K39/118

公开(公告)号：US12121576B2

公开(公告)日：2024-10-22

申请号：US18318093

申请日：2023-05-16

Applicant: Zoetis Services LLC

Inventor： Paul Joseph Dominowski ,  Dennis L. Foss ,  Guillermo Gallo ,  John Morgan Hardham ,  Richard Lee Krebs ,  Sandra Ann Marie Lightle ,  Suman Mahan ,  Sangita Mediratta ,  Kaori Mohr ,  Duncan Mwangi ,  Sharath K. Rai ,  Sarah A. Salmon ,  Shaunak Vora ,  Lauren Wilmes

IPC: A61K39/00 ,  A61K39/002 ,  A61K39/012 ,  A61K39/05 ,  A61K39/08 ,  A61K39/085 ,  A61K39/09 ,  A61K39/108 ,  A61K39/118 ,  A61K39/12 ,  A61K39/39 ,  C12N7/00 ,  G01N33/569

CPC classification number: A61K39/092 ,  A61K39/0002 ,  A61K39/0003 ,  A61K39/0005 ,  A61K39/002 ,  A61K39/012 ,  A61K39/0258 ,  A61K39/05 ,  A61K39/08 ,  A61K39/085 ,  A61K39/118 ,  A61K39/12 ,  A61K39/39 ,  G01N33/56944 ,  A61K2039/552 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/55583 ,  G01N2333/315 ,  G01N2469/10 ,  Y02A50/30

Abstract: The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.

公开(公告)号：US11701433B2

公开(公告)日：2023-07-18

申请号：US16619802

申请日：2018-06-01

Applicant: The Regents of the University of Michigan

Inventor： Yu Lei ,  Yee Sun Tan ,  Kanokwan Sansanaphongpricha ,  Duxin Sun ,  Hongwei Chen ,  Hongxiang Hu

IPC: A61K9/00 ,  A61K47/69 ,  A61K47/64 ,  A61P35/00 ,  A61K39/00 ,  A61K39/02 ,  A61K39/118 ,  A61K39/385 ,  B82Y5/00

CPC classification number: A61K47/6929 ,  A61K39/0003 ,  A61K39/0011 ,  A61K39/02 ,  A61K39/118 ,  A61K39/385 ,  A61K47/643 ,  A61K47/646 ,  A61K47/6923 ,  A61P35/00 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/60 ,  A61K2039/622 ,  B82Y5/00

Abstract: The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and/or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) an type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

公开(公告)号：US11229699B2

公开(公告)日：2022-01-25

申请号：US16759945

申请日：2018-11-05

Applicant: Intervet Inc.

Inventor： Ian Tarpey

IPC: A61K39/12 ,  C12N7/00 ,  A61K39/295 ,  A61K39/118 ,  A61K39/00

Abstract: The present invention provides new feline calicivirus vaccines, including multivalent vaccines. The present invention also provides methods of making and using the vaccines.

公开(公告)号：US20220008532A1

公开(公告)日：2022-01-13

申请号：US17488961

申请日：2021-09-29

Applicant: Intervet Inc.

Inventor： Zhichang Xu ,  Rhonda LaFleur ,  Ian Tarpey

IPC: A61K39/295 ,  A61K39/118 ,  A61K39/12 ,  C12N7/00

Abstract: The present invention provides new multivalent vaccines for felines. The present invention also provides methods of making and using the multivalent vaccines alone or in combinations with other protective agents.

公开(公告)号：US20210252127A1

公开(公告)日：2021-08-19

申请号：US17053544

申请日：2019-05-03

Applicant: UNIVERSITY OF KANSAS

Inventor： Wendy L. PICKING ,  William D. PICKING

IPC: A61K39/118 ,  A61K39/02 ,  A61K39/104

Abstract: Disclosed are methods and compositions related to polypeptides comprising a fusion of the needle tip protein and translocator protein of a type III secretion apparatus (T3SA) from a type III secretion system (T3SS) of a Gram negative bacteria. Disclosed herein are fusion polypeptides comprising a fusion of a needle tip protein, such as, Bsp22, LcrV, BipD, PcrV, CT053, or CT668, or anantigenic fragment thereof; and a translocator protein, such as, BopB, YopB, BipB, PopB, CopB, or CopB2, or anantigenic fragment thereof from a Type III secretion system (T3SS) of a Gram negative bacteria, such as, Bordetella, Burkholderia, Chlamydia, Pseudomonas, Vibrio, or Yersinia.

公开(公告)号：US20210213129A1

公开(公告)日：2021-07-15

申请号：US17216819

申请日：2021-03-30

Applicant: Immugen Pharma LLC

Inventor： Craig Travis

IPC: A61K39/39 ,  A61K39/04 ,  A61K39/02 ,  A61K39/05 ,  A61K39/118 ,  A61K39/085 ,  A61K39/095 ,  A61K39/08 ,  A61K39/104 ,  A61K39/112 ,  A61K39/29 ,  A61K39/225 ,  A61K39/215 ,  A61K39/145 ,  A61K39/13 ,  A61K39/165 ,  A61K39/20 ,  A61K39/205 ,  A61K39/25 ,  A61K39/00 ,  A61K39/015 ,  A61K39/008 ,  A61K39/005 ,  A61K39/002 ,  A61K39/012

Abstract: Disclosed are methods and compositions related to the use cannabinoids as adjuvants for the accelerated induction and production of an antibody based immune response.

公开(公告)号：US20210106668A1

公开(公告)日：2021-04-15

申请号：US16496686

申请日：2018-03-23

Applicant: Ohio State Innovation Foundation

Inventor： Thomas CHERPES ,  Rodolfo D. VICETTI MIGUEL ,  Natividad RUIZ

IPC: A61K39/118 ,  C07K14/295

Abstract: Disclosed herein is a recombinant Chlamydia-activated B cell (CAB) platform, vaccines, and methods of using the same. Disclosed is a method of enhancing a population of B cells, comprising exposing said B cells to a recombinant polypeptide derived from a Chlamydia spp. under conditions suitable to enhance the population of B cells, such that expansion and differentiation of said B cells takes place, and said B cells are exposed or crosslinked to an antigen. Also disclosed are methods to use a recombinant polypeptide derived from a Chlamydia spp. as an adjuvant for induction of enhanced humoral immunity against an unrelated antigen (e.g., humoral immunity against HIV antigen). Also disclosed are methods of producing said CABs, and treating a subject in need thereof with said CABs.